As Vaping Expands, Smoking Keeps Falling: New Zealand and U.S. Data Strengthen the Case for Tobacco Harm Reduction

New Zealand’s latest tobacco figures are adding weight to a pattern increasingly difficult for policymakers to overlook: countries where smokers have meaningful access to vaping are continuing to record historically low levels of cigarette use. The country’s 2025 tobacco returns show the volume of smoked tobacco entering the legal retail market fell 22% in a single year and 58% compared with 2015. While New Zealand Health Survey data put daily adult smoking at 6.8% in 2024/25, down from 16.4% in 2011/12. The estimated number of daily smokers has nearly halved over that period.

The trend has coincided with the emergence of vaping as a mainstream alternative. Daily vaping increased from just 0.9% in 2015/16 to 11.7% in 2024/25. New Zealand’s Ministry of Health cautions that these parallel trends cannot establish that vaping caused the decline in smoking. Nevertheless, the substitution pattern is notable: as vaping became increasingly established, smoking moved sharply in the opposite direction.

For the Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA), New Zealand provides a particularly relevant case study for neighbouring governments that continue to prohibit or heavily restrict lower-risk nicotine products. Executive Coordinator Nancy Loucas argues that the results challenge predictions that regulated vaping access would derail progress against cigarettes.

New Zealand is hardly alone in demonstrating that widespread availability of novel nicotine products does not inevitably lead to higher smoking prevalence. The latest U.S. National Youth Tobacco Survey provides another striking example. In 2025, just 1.4% of middle and high school students reported currently smoking cigarettes. Meanwhile, vaping was 5.2%, while nicotine pouch use remained comparatively low at 1.7%. Overall youth use of cigarettes, vaping products and tobacco products declined between 2022 and 2025.

These figures contrast dramatically with the U.S. youth smoking epidemic of previous decades. They also complicate the argument that introducing alternative nicotine products must inevitably renormalise cigarette smoking. Naturally, population trends alone cannot prove vaping caused declining smoking rates; taxation, smoke-free laws, changing social attitudes, prevention campaigns and other factors all contribute.

Yet the much-feared and discussed reversal in cigarette-smoking declines following the arrival of e-cigarettes has not materialised. Instead, cigarettes have become increasingly uncommon among young Americans while vaping has also retreated substantially from its 2019 peak.

That distinction is really important. While it’s crucial to prevent young people from starting nicotine, tackling vaping and eliminating smoking are not the same public health goals. Cigarettes are especially dangerous since the combustion process creates a toxic mix that leads to most tobacco-related diseases.

Beyond population trends, randomised controlled trials now show much more convincing evidence that vaping can actually help adult smokers quit. The latest update of the Cochrane living systematic review, which includes data up to January 2026, found with high certainty that nicotine e-cigarettes lead to higher smoking cessation rates compared to conventional nicotine replacement therapy (NRT).

In seven trials with 2,544 participants, nicotine vaping increased quit rates by 59% compared to NRT. To put it simply, about eight to ten out of every 100 people using nicotine e-cigarettes managed to quit for at least six months, while roughly six out of 100 who used patches, gum, or other NRT were successful.

That places vaping firmly within the evidence-based smoking cessation toolkit rather than merely making it an alternative consumer product.

Other smoke-free nicotine technologies may broaden that toolkit further. Nicotine pouches eliminate both tobacco combustion and inhalation, potentially providing another option for smokers who do not want to vape. Their evidence base specifically for smoking cessation remains less developed than that for e-cigarettes, so claims of cessation effectiveness should remain proportionate to the available research. Their toxicological profile, however, differs fundamentally from combustible cigarettes because they do not generate smoke.

New Zealand has increasingly attempted to combine adult access with measures intended to prevent youth uptake. Its government explicitly recognises less harmful alternatives such as vaping as practical tools for smokers trying to quit. CAPHRA argues that this approach deserves particular consideration across Asia, where millions continue to smoke while several governments favour prohibition or severe restrictions on vaping.

Clarisse Virgino, CAPHRA’s Philippines representative, maintains that the central policy mistake is treating every nicotine product as though it carries the same level of risk. A risk-proportionate system would instead distinguish combustible cigarettes from non-combustible alternatives while enforcing age restrictions and product standards.

There are important qualifications. New Zealand authorities acknowledge that illicit cigarettes could account for part of the accelerated reduction in legal tobacco sales, while persistent smoking inequalities remain, particularly among Māori and more deprived communities. These challenges reinforce the need for targeted cessation support rather than complacency.

The broader evidence nevertheless presents policymakers with a clearer choice. Countries can attempt to eliminate nicotine use altogether, potentially restricting alternatives alongside the cigarettes responsible for the overwhelming burden of disease. Or they can pursue the more pragmatic objective of eliminating smoking by encouraging consumers who cannot or will not quit nicotine to move down the risk continuum.

New Zealand’s experience may not prove that vaping alone caused its remarkable decline in smoking. However, it does show that widespread access to vaping goes hand in hand with decreased smoking rates.

Combined with historically low U.S. youth smoking and high-certainty clinical evidence that nicotine vapes outperform NRT for cessation, the case for tobacco harm reduction is becoming increasingly difficult to dismiss. The priority should remain the product causing the greatest harm: combustible cigarettes.

https://www.vapingpost.com/2025/11/24/punished-for-success-new-zealands-dirty-ashtray-reveals-the-fctcs-embedded-bias/